Adenovirus-Based Cancer Therapy Shows Promise with Low-Dose Cisplatin

Strategic Insights -

Cancer Gene Therapy research has made significant progress in Seoul, South Korea, as a team of scientists from Seoul National University has been studying the effects of combining adenovirus-based gene therapy with low-dose cisplatin in treating head and neck cancer. The researchers discovered that the combination of these two treatments resulted in enhanced tumor regression and improved immune clearance of cancer cells.

Key Takeaways:

  • The adenovirus harboring the HSV thymidine kinase (HSVtk) gene under the regulation of a trans-splicing ribozyme that targets telomerase (Ad5mTR) is cytotoxic to cancer cells by inhibiting DNA replication.
  • Low-dose cisplatin (1 mg/kg) added to Ad5mTR therapy enhances tumor regression and increases the number of E7-specific CD8+ T cells inside tumors.
  • The combination of Ad5mTR and low-dose cisplatin resulted in improved immune clearance of cancer cells and enhanced tumor clearance.
  • The research suggests that the addition of low-dose cisplatin to Ad5mTR therapy potentiates CD8+ T-cell-mediated anti-tumor immunity.
  • The study focused on HPV16-associated tonsillar carcinoma, a type of head and neck cancer.

Statistics:

  • The researchers observed a 40% increase in the number of E7-specific CD8+ T cells inside tumors.
  • Low-dose cisplatin (1 mg/kg) alone had no tumor-suppressive effects.
  • The combination of Ad5mTR and low-dose cisplatin resulted in additional therapeutic benefits for HPV16-positive head and neck cancer patients.

Sources:

  • Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma. Cancer Letters (2015);356(2):743-750.
  • Seoul National University, Coll Med, Seoul, South Korea. (Contact: A.R. Goh)